Efficacy of finerenone in reducing proteinuria in diabetic kidney disease with maximum tolerable doses of dapagliflozin and telmisartan

Table 1 Baseline characteristics of study participants (n = 33), n (%)/mean ± SD

Characteristic	Value
Number of participants	33
Age (years)	59.5 ± 10.4
Gender (male)	30 (90.9)
Baseline eGFR (mL/minute/1.73 m2)	36.3 ± 10.2
Baseline serum creatinine (mg/dL)	2.11 ± 0.43
Baseline UACR (mg/g)	Median: 1656.0 (range: 5.57-9699.00)
Baseline serum potassium (mmol/L)	4.33 ± 0.53
Duration of diabetes (years)	17.3 ± 8.9

UACR: Urinary albumin-to-creatinine ratio; eGFR: Estimated glomerular filtration rate.

Table 2 Baseline vs follow-up clinical values, mean ± SD

Parameter	Baseline	Follow-up	Change (%)	P value	Effect size (Cohen’s d)	95%CI
Serum potassium (mmol/L)	4.33 ± 0.53	4.60 ± 0.50	↑ 6.4%	0.016	0.45	-0.75 to 1.55
UACR (mg/g)	2512.7 ± 2396.2	2274.6 ± 2379.8	-9.5%	0.256	-0.20	-2820.4 to 2143.9

UACR: Urinary albumin-to-creatinine ratio.

Table 3 Baseline characteristics showing no significant differences between responders and non-responders, mean ± SD

Variable	Responders (n = 22)	Non-responders (n = 11)	P value
Age (years)	56.2 ± 8.9	59.1 ± 7.6	0.257
Duration of diabetes (months)	128.3 ± 46.7	135.9 ± 51.2	0.612
eGFR (ml/minute/1.73 m2)	41.5 (34.2-48.8)	38.6 (32.1-46.4)	0.276
Serum potassium (mmol/L)	4.6 (4.3-4.9)	4.7 (4.4-5.0)	0.720

eGFR: Estimated glomerular filtration rate.